Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Jul;36(1):75–77. doi: 10.1111/j.1365-2125.1993.tb05896.x

Stereoselective disposition of (+/-)-sotalol at steady-state conditions.

C Fiset 1, F Philippon 1, M Gilbert 1, J Turgeon 1
PMCID: PMC1364559  PMID: 8373714

Abstract

The objective of this study was to assess, under steady-state conditions, the stereoselective disposition of (+/-)-sotalol in man. In all patients studied (n = 7) values of oral clearance (137 +/- 51 ml min-1), renal clearance (96 +/- 42 ml min-1) and nonrenal clearance (41 +/- 25 ml min-1) of (-)-sotalol were greater than those for (+)-sotalol (123 +/- 45 ml min-1, 89 +/- 39 ml min-1 and 34 +/- 23 ml min-1, respectively; P < 0.05, Student's paired t-test). Binding to plasma proteins was greater for (+)-sotalol (38 +/- 9% vs 35 +/- 9% for the (-)-enantiomer; P < 0.05) such that unbound oral clearance (+)/(-) ratio (0.95 +/- 0.06) and unbound renal clearance (+)/(-) ratio (0.97 +/- 0.06) were not stereoselective. In contrast, estimated unbound nonrenal clearance, which represents approximately 25% of the total unbound clearance of the drug, was greater for the (-)-enantiomer (64 +/- 42 ml min-1) compared with (+)-sotalol (57 +/- 42 ml min-1; P < 0.05). The difference in the pharmacokinetics of sotalol enantiomers is mainly related to stereoselectivity in plasma protein binding.

Full text

PDF
75

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anttila M., Arstila M., Pfeffer M., Tikkanen R., Vallinkoski V., Sundquist H. Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol (Copenh) 1976 Jul;39(1):118–128. doi: 10.1111/j.1600-0773.1976.tb03162.x. [DOI] [PubMed] [Google Scholar]
  2. Carr R. A., Foster R. T., Bhanji N. H. Stereospecific high-performance liquid chromatographic assay of sotalol in plasma. Pharm Res. 1991 Sep;8(9):1195–1198. doi: 10.1023/a:1015870805757. [DOI] [PubMed] [Google Scholar]
  3. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  4. Fiset C., Philippon F., Gilbert M., Turgeon J. Stereoselective high-performance liquid chromatographic assay for the determination of sotalol enantiomers in biological fluids. J Chromatogr. 1993 Feb 26;612(2):231–237. doi: 10.1016/0378-4347(93)80168-4. [DOI] [PubMed] [Google Scholar]
  5. Fitzgerald J. D. Perspectives in adrenergic beta-receptor blockade. Clin Pharmacol Ther. 1969 May-Jun;10(3):292–306. doi: 10.1002/cpt1969103292. [DOI] [PubMed] [Google Scholar]
  6. Hafner D., Berger F., Borchard U., Kullmann A., Scherlitz A. Electrophysiological characterization of the class III activity of sotalol and its enantiomers. New interpretation of use-dependent effects. Arzneimittelforschung. 1988 Feb;38(2):231–236. [PubMed] [Google Scholar]
  7. Kato R., Ikeda N., Yabek S. M., Kannan R., Singh B. N. Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol. 1986 Jan;7(1):116–125. doi: 10.1016/s0735-1097(86)80268-6. [DOI] [PubMed] [Google Scholar]
  8. Poirier J. M., Jaillon P., Lecocq B., Lecocq V., Ferry A., Cheymol G. The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers. Eur J Clin Pharmacol. 1990;38(6):579–582. doi: 10.1007/BF00278585. [DOI] [PubMed] [Google Scholar]
  9. Sallustio B. C., Morris R. G., Horowitz J. D. High-performance liquid chromatographic determination of sotalol in plasma. I. Application to the disposition of sotalol enantiomers in humans. J Chromatogr. 1992 May 8;576(2):321–327. doi: 10.1016/0378-4347(92)80206-6. [DOI] [PubMed] [Google Scholar]
  10. Schnelle K., Klein G., Schinz A. Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man. J Clin Pharmacol. 1979 Aug-Sep;19(8-9):516–522. doi: 10.1002/j.1552-4604.1979.tb02517.x. [DOI] [PubMed] [Google Scholar]
  11. Somani P., Watson D. L. Antiarrhythmic activity of the dextro- and levorotatory isomers of 4-(2-isopropylamino-1-hydroxyethyl) methanesulfonanilide (MJ 1999). J Pharmacol Exp Ther. 1968 Dec;164(2):317–325. [PubMed] [Google Scholar]
  12. Strauss H. C., Bigger J. T., Jr, Hoffman B. F. Electrophysiologial and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res. 1970 Jun;26(6):661–678. doi: 10.1161/01.res.26.6.661. [DOI] [PubMed] [Google Scholar]
  13. Sundquist H., Anttila M., Simon A., Reich J. W. Comparative bioavailability and pharmacokinetics of sotalol administered alone and in combination with hydrochlorothiazide. J Clin Pharmacol. 1979 Aug-Sep;19(8-9):557–564. doi: 10.1002/j.1552-4604.1979.tb02522.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES